Editorial Policy
How we grade evidence, what we refuse to publish, and how to hold us to it.
How we grade evidence
Not all evidence is equal, and a page that presents a single mouse study with the same confidence as a meta-analysis is misleading whether or not every individual sentence is technically true. We use three labels and try to signal which applies.
| Label | What it means | Example on this site |
|---|---|---|
| Established | Replicated human evidence, or basic physiology not in dispute | Cortisol raises hepatic glucose output; chromium is involved in insulin action |
| Supported but limited | Reasonable human evidence with real caveats — small trials, mixed results, or effects concentrated in specific groups | Chromium supplementation benefits concentrated in low-status individuals; gymnema's modern trial base |
| Preliminary | Mechanistically plausible, thin or contested human evidence | Maca's adaptogenic effects; African mango's weight and appetite trials |
What counts as a source
- Preferred: systematic reviews and meta-analyses, randomised controlled trials in humans, and guidance from bodies such as the NIH Office of Dietary Supplements, NIDDK, NCCIH, the FDA and the American Diabetes Association.
- Used with caveats stated: small single trials, observational studies, and mechanistic work.
- Not used as evidence of human effect: in-vitro studies and animal work presented on their own. These can explain a mechanism; they cannot establish that something works in people.
- Never used: other supplement marketing pages, undated content farms, and studies cited second-hand without checking what they actually reported.
What we will not publish
- That GlucoBliss treats, cures, prevents or reverses diabetes or prediabetes.
- Any suggestion of reducing, stopping or delaying prescribed medication.
- Claims of regenerating pancreatic beta cells.
- Any discussion of glucose-lowering botanicals without the hypoglycaemia interaction warning.
- Testimonials framed as typical or expected results.
- Before-and-after imagery implying clinical outcomes.
- A study cited for a conclusion it does not support.
- Fabricated urgency presented as fact.
Our conflict of interest
We sell GlucoBliss and we profit from sales made here. That is a real conflict and it should shape how you read everything on this site.
Our response to it is to publish the things a purely commercial site would omit: the interaction risks, the weak evidence for African mango, the fact that the finished formula has no trial of its own, the criticisms of our own pricing structure, and the repeated statement that sleep, post-meal movement and meal composition all outperform any supplement in this category.
You should still read us sceptically. We would rather earn a sale from someone who did.
Why we are strict about this
Blood sugar content sits in the category search engines and clinicians alike treat as high-stakes: information that could affect someone's health decisions. Someone who reads a supplement page, concludes their medication is optional and stops taking it can end up seriously unwell.
That is not a hypothetical concern in this category. It is the specific reason our reviewer's veto list exists, and the reason every page carries the same disclaimer even where it feels repetitive.
Updates and corrections
Pages show a last-reviewed date. Safety and interaction content is re-reviewed when guidance changes. Corrections go to support@gluccobliss.com and substantive ones are made to the page with the date updated.